OKYO Pharma (OKYO) Competitors $2.75 -0.01 (-0.36%) Closing price 07/25/2025 03:58 PM EasternExtended Trading$2.76 +0.00 (+0.18%) As of 07/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO vs. HUMA, ATXS, PRTA, RCKT, FHTX, GLUE, AURA, ALT, ABEO, and INBXShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Humacyte (HUMA), Astria Therapeutics (ATXS), Prothena (PRTA), Rocket Pharmaceuticals (RCKT), Foghorn Therapeutics (FHTX), Monte Rosa Therapeutics (GLUE), Aura Biosciences (AURA), Altimmune (ALT), Abeona Therapeutics (ABEO), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Its Competitors Humacyte Astria Therapeutics Prothena Rocket Pharmaceuticals Foghorn Therapeutics Monte Rosa Therapeutics Aura Biosciences Altimmune Abeona Therapeutics Inhibrx Biosciences OKYO Pharma (NASDAQ:OKYO) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Is OKYO or HUMA more profitable? Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Humacyte N/A N/A -73.59% Does the media refer more to OKYO or HUMA? In the previous week, Humacyte had 4 more articles in the media than OKYO Pharma. MarketBeat recorded 7 mentions for Humacyte and 3 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.40 beat Humacyte's score of 0.12 indicating that OKYO Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Humacyte 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate OKYO or HUMA? OKYO Pharma presently has a consensus target price of $7.00, suggesting a potential upside of 154.55%. Humacyte has a consensus target price of $11.71, suggesting a potential upside of 363.02%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, OKYO or HUMA? OKYO Pharma has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Which has better valuation and earnings, OKYO or HUMA? OKYO Pharma has higher earnings, but lower revenue than Humacyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$4.71MN/AN/AHumacyte$1.57M249.97-$148.70M-$0.69-3.67 Do institutionals and insiders hold more shares of OKYO or HUMA? 3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 5.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryHumacyte beats OKYO Pharma on 7 of the 11 factors compared between the two stocks. Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.81M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E RatioN/A21.1828.3320.08Price / SalesN/A282.17430.8989.29Price / CashN/A42.7636.2258.56Price / Book-13.758.378.675.88Net Income-$4.71M-$55.19M$3.25B$258.89M7 Day Performance-8.03%5.86%4.23%3.71%1 Month Performance13.64%17.29%10.50%11.72%1 Year Performance102.06%4.39%34.42%18.00% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma2.9241 of 5 stars$2.75-0.4%$7.00+154.5%+103.7%$103.81MN/A0.007HUMAHumacyte1.6488 of 5 stars$2.31+0.2%$11.71+408.2%-69.0%$357.55M$1.57M-3.34150News CoverageAnalyst ForecastATXSAstria Therapeutics1.9099 of 5 stars$6.27+0.1%$30.00+378.9%-44.4%$353.56MN/A-3.3530PRTAProthena3.7406 of 5 stars$6.52+3.6%$31.50+383.5%-73.1%$351.30M$135.16M-3.14130Positive NewsRCKTRocket Pharmaceuticals4.8425 of 5 stars$3.28+4.6%$18.60+467.9%-87.9%$349.72MN/A-1.25240Trending NewsAnalyst ForecastAnalyst RevisionGap DownFHTXFoghorn Therapeutics2.1319 of 5 stars$6.27+2.7%$12.13+93.5%-5.1%$347.65M$22.60M-4.59120News CoverageGLUEMonte Rosa Therapeutics2.0136 of 5 stars$5.64-3.3%$15.33+172.1%+21.4%$346.61M$75.62M70.4590AURAAura Biosciences2.6553 of 5 stars$6.82+0.7%$22.00+222.8%-29.6%$342.59MN/A-3.5950News CoveragePositive NewsALTAltimmune2.1026 of 5 stars$4.21+3.8%$18.20+332.8%-39.0%$341.07M$20K-3.3450ABEOAbeona Therapeutics3.7549 of 5 stars$6.57-2.7%$19.25+193.2%+29.8%$336.87MN/A-5.1990INBXInhibrx Biosciences3.1534 of 5 stars$23.07+4.3%N/A+71.9%$333.98M$200K0.20166Positive News Related Companies and Tools Related Companies HUMA Alternatives ATXS Alternatives PRTA Alternatives RCKT Alternatives FHTX Alternatives GLUE Alternatives AURA Alternatives ALT Alternatives ABEO Alternatives INBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKYO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
